Oric Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company that sets new benchmarks in the world of cancer treatment. Established in 2014, and based in South San Francisco, California, the company is esteemed for its dedication to overcoming treatment resistance in cancer patients.
Oric Pharmaceuticals upholds a mission to "discovery the undiscovered," which involves extensively researching and developing novel treatments that can strategically counteract the mechanisms by which cancers fight back against treatment. They believe that by discovering these resistance mechanisms, they can create therapies that limit the effectiveness of tumors and overcome resistance to see effective results in treating cancer.
The company has an impressive pipeline of product candidates. Its leading candidate is ORIC-101, which demonstrates important functions in multiple resistance mechanisms to various cancer therapies. This small molecule glucocorticoid receptor antagonist is being developed for solid tumors resistant to checkpoint inhibition and metastatic prostate cancer. Beyond ORIC-101, there are also three other drugs at different stages of development set to cater to different types of cancer.
ORIC's research, backed by high scientific rigor, targets the significant needs of patients who do not respond, or no longer respond to current cancer therapies. Their staff consists of scientific pioneers and experienced drug developers who continue to augment the company's drug pipeline.
In addition to its leading innovations in cancer treatment, ORIC is also known for its strong collaborations with noted biotech and pharma companies. Over the years, the company has managed to secure persistent funding from leading venture capital firms, industry partners, public investors and non-profit partners.
Interestingly, the term ORIC stands for 'Overcoming Resistance In Cancer,' reflecting the company's relentless determination and commitment to fight cancer. This also underscores the company's ethos in continuously seeking ways to outsmart cancer and its adaptability to resist treatment. They expose the cancer's playbook, target treatment, and help more people overcome the disease.
Oric Pharmaceuticals went public in April 2020, joining the NASDAQ under the ticker symbol "ORIC." Despite the challenges of the Covid-19 pandemic, the company has continued to make incredible strides in its quest to bring novel, effective cancer treatments to patients. Its relentless pursuit of pioneering techniques to overcome resistance distinguishes ORIC Pharmaceuticals, Inc. as a beacon of hope in the cancer treatment landscape.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bank of America Corp DE recently acquired 1,078,055 shares of Oric Pharmaceuticals (NASDAQ:ORIC), valued at approximately $11.7 million, representing about 1.04% of the company. Institutional investors now own 95.05% of ORIC, and analysts maintain a "Moderate Buy" consensus with an average price target of $20.18. The company recently reported a quarterly loss of $0.38 per share, missing estimates, and its CFO sold 77,000 shares under a pre-arranged trading plan.
Oric Pharmaceuticals (NASDAQ:ORIC) shares gapped up before market open but traded down to $13.3950. The company, a clinical-stage cancer biopharmaceutical firm, reported a quarterly loss of $0.38 per share and has a "Moderate Buy" consensus rating from analysts with an average price target of $20.18. Despite a CFO selling over 77,000 shares, institutional investors own 95.05% of the stock.
HC Wainwright has revised down its earnings per share forecasts for Oric Pharmaceuticals (NASDAQ:ORIC) for Q3 2026 and FY2026, projecting larger losses. Despite the more pessimistic outlook, HC Wainwright maintained a "Buy" rating and a $27 price target on the stock. Oric Pharmaceuticals recently missed its Q2 earnings consensus, reporting a loss of $0.38 per share against an estimate of $0.36.
This article provides an analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), focusing on momentum shifts and potential trading strategies based on AI models. It highlights strong near and mid-term sentiment, identifies compelling upside potential due to the absence of resistance levels, and offers specific position, momentum breakout, and risk hedging trading strategies. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
H.C. Wainwright has raised its target price for ORIC Pharmaceuticals, Inc. from $25 to $27. This adjustment suggests a positive outlook from the analytical firm regarding the company's future performance. The news was reported by Reuters.
ORIC Pharmaceuticals (ORIC) has garnered attention after reporting Q2 2026 results, showing wider net losses but improved basic loss per share, alongside significant share price momentum. The company's price-to-book ratio of 3.7x is below its direct peer average but above the broader US Biotechs industry average, indicating mixed market valuation signals. Despite being unprofitable and forecasting continued losses, the current valuation reflects expectations stronger than the sector but more cautious than its direct peer group.